Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | exonuclease III APE | 0.0019 | 0.4151 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.4151 | 0.5 |
Echinococcus multilocularis | lamin | 0.0027 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0019 | 0.4151 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.4151 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0019 | 0.4151 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0019 | 0.4151 | 0.3482 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 0.4151 | 0.4151 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 0.4151 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0019 | 0.4151 | 0.4151 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.4151 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 0.4151 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0019 | 0.4151 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 1 | 1 |
Onchocerca volvulus | 0.0027 | 1 | 0.5 | |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.4151 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 0.4151 | 0.5 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0014 | 0.1026 | 0.1026 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.9646 | 0.9646 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 0.4151 | 0.4151 |
Echinococcus multilocularis | musashi | 0.0027 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.4151 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0027 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0027 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0.4151 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0027 | 1 | 1 |
Onchocerca volvulus | 0.0027 | 1 | 0.5 | |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0.4151 | 0.5 |
Schistosoma mansoni | lamin | 0.0027 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.4151 | 0.5 |
Schistosoma mansoni | lamin | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0027 | 1 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0027 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0027 | 1 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0027 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | > 50 uM | Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay | ChEMBL. | 25062006 |
Inhibition (binding) | = 1.6 % | Inhibition of recombinant human DNA topoisomerase 2alpha assessed as relaxation of supercoiled DNA pBR322 at 20 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis | ChEMBL. | 25062006 |
Inhibition (binding) | = 8.4 % | Inhibition of recombinant human DNA topoisomerase 1 assessed as relaxation of supercoiled DNA pBR322 at 100 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis | ChEMBL. | 25062006 |
Inhibition (binding) | = 31.3 % | Inhibition of recombinant human DNA topoisomerase 2alpha assessed as relaxation of supercoiled DNA pBR322 at 100 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis | ChEMBL. | 25062006 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.